

Course Competency

RET 2350 RESPIRATORY CARE PHARMACOLOGY

Course Description

This course is designed to provide training in the basic principles of the administration of medications including dosage and solutions. The drugs administered by respiratory therapists are covered in -depth, along with an introduction to the general pharmacological classifications of other drugs that may be administered to pulmonary patients. Prerequisites: CHM 1033, RET 1484, 1484L; Corequisites: RET 2503, 2275, 2275L. (2 hr. lecture)

Course Competency	Learning Outcomes
Competency 1: The student will describe the general concepts related to pharmacological therapy by:	 Communication Numbers / Data Critical thinking Information Literacy Ethical Issues
 Describing a drug's trade naming, generic naming, therapeutic dose, and side effects; determining whether it is a teratogen or carcinogen, when provided with the drug's information. Describing the four phases of drug development. Describing some aspects of governmental control of the abuse of prescription drugs and reviewing the five schedules of drugs as defined by the Federal Comprehensive Drug Abuse Prevention and Control Act of 1970. Listing the sources from where detailed and up-to-date information about drugs can be obtained. Defining pharmacology and describing several disciplines within the area of pharmacologic study. Comparing and contrasting the different routes of medication administration. Determining the safety of a drug by 	

- calculating the therapeutic index.
- 8. Predicting the action or effect of a receptor agonist and antagonist.
- 9. Explaining how lipid solubility and ionization affect absorption of medications.
- 10. Identifying the patient factors that may alter drug effects.
- 11. Describing the process of drug metabolism and excretion and listing the most common organs responsible for each.
- 12. Describing the overall function and differences between the somatic nervous system, the sympathetic division, and the parasympathetic division of the autonomic nervous system.
- 13. Explaining the function of neurotransmitters.
- 14. Comparing and contrasting the sites of action, neurotransmitters at the ganglion site, and neuroeffector sites of somatic, the sympathetic, and the parasympathetic nervous systems.
- 15. Listing the characteristic physiologic functions that are controlled by the sympathetic and parasympathetic divisions.
- 16. Identifying If given an adrenergic agonist drug and the receptors it acts on, and be able to predict its effects on the blood vessels, heart, and lungs.
- 17. Determining the effects each α-blocking & β-blocking drug will have on the patient's vital signs and listing the possible side effects when given a patient's case with low blood pressure.
- 18. Describing the mechanism by which the choline esters and anticholinesterase drugs work and the clinical effects one would expect to see with their use.
- 19. Explaining in which clinical situations you would use an anticholinergic agent and what clinical and toxic effects you would expect to see.
- 20. Explaining in which clinical situations you would use an anticholinergic agent and what clinical and toxic effects you would

expect to see. 21. Calculating an appropriate dosage of medication in both weight (milligram) and volume (milliliter) and converting medication dosages from one system to the other. 22. Determining dosages of reconstituted medications. 23. Converting metric dosage measures into household units. 24. Determining the appropriate volumes of drugs and diluents for administering continuous bronchodilator aerosol therapy using proportions. 25. Determining drug doses using percentage strength solutions. 1. Communication **Competency 2:** The student will describe the 2. Numbers / Data function of the electrical conduction system of 3. Critical thinking the heart assessing its function by ECG 4. Information Literacy interpretation by: 5. Computer / Technology Usage 1. 1. Describing the characteristics of an aerosol solution that leads to more effective drug delivery into the lung tissue. 2. Listing the advantages and disadvantages of drug administration by the aerosol route. 3. Describing the equipment used for aerosol administration of drugs by small-volume nebulizer (SVN) and the procedure that should be followed. 4. Describing patient instructions for taking an effective SVN treatment. 5. Describing the purpose of a spacer or valved holding chamber device for aerosol administration. 6. Describing patient instructions for taking an effective dose of medication by MDI, including the use of a spacer or holding chamber. 7. Describing the use of SVN and MDI and aerosol medications during continuous mechanical

ventilation, including placement of these devices in the ventilator circuit. 8. Listing

the drugs that are currently administered by powder aerosol (dry poser inhaler), including the devices used for this administration. 9. Listing the indications (for clinical settings) for drug administration by instillation and the disadvantages or hazards of drug administration by instillation. 10. Comparing and contrasting nebulizers, MDI, and dry powder inhalers for aerosol drug delivery. 11. Recommending the appropriate method for medication delivery, when given a patient case study. 12. Comparing and contrasting bronchoconstriction and bronchospasm. 13. Listing the three categories of bronchodilators and describing the mechanism of how each class causes bronchodilation. 14. Describing the common adverse effects and contraindications of sympathomimetic, anticholinergic, and methylxanthine bronchodilators. 15. Listing the common drugs that interact with sympathomimetic, anticholinergic, and methylxanthine bronchodilators and predicting the potential effect of using the drugs concomitantly. 16. Comparing the use of adrenergic, anticholinergic, and methylxanthine bronchodilators in clinical practice. 17. Assessing the clinical indications for short-acting and longacting inhaled bronchodilators. 18. Suggesting the most appropriate bronchodilator therapy including the drug of choice and route of administration, given a patient case study. 19. Describing mucosal edema and how it relates to difficulty breathing or respiratory distress. 20. Listing the clinical conditions or diseases that may lead to bronchoconstriction caused by mucosal edema and therapies used for the treatment. 21. Recommending a dose and listing the important adverse effects that need monitoring and special consideration sin the use of racemic epinephrine. 22.

Describing the pathophysiology of asthma and the rationale for using corticosteroid therapy for control of asthmatic symptoms. 23. Describing the mechanism of action of corticosteroids used in the treatment of airway inflammation. 24. Listing the brand and generic naming of inhaled corticosteroids used in the treatment of airway inflammation as well as its adverse effects and contraindications. 25. Describing the mechanism of action of leukotriene inhibitors and antagonists. 26. Distinguishing between controlled and uncontrolled asthmatic patients and determining who would benefit most from the use of a monoclonal antibody. 27. Suggesting the most appropriate drug therapy, including the drug(s) of choice, route of delivery, and recommending dosage(s), given a patient case study. 28. Comparing and contrasting the causes of mucus dysfunction in asthma, chronic obstructive pulmonary disease, and cystic fibrosis patients. 29. Defining the terms bland aerosol, mucoactive, mucolytic, mucokinetic, and expectorant. 30. Describing the therapeutic indications for the use of bland aerosols and mucolytic agents in airway maintenance. 31. Comparing and contrasting the two primary mucolytic aerosols. 32. Describing the proposed mechanisms of action, contraindications, and hazards of each mucolytic agent. 33. Describing the use of sodium bicarbonate as an expectorant or thinning agent 34. Suggesting the most appropriate mucolytic therapy, including the drug of choice, route of delivery, and recommended dosage, given a case study

2. 1. Defining surface tension and describing the clinical importance of surface tension as it relates to the work of breathing. 2. Describing the physiologic purpose of pulmonary surfactant. 3. Describing the clinical indications for the use of surfactant replacement drugs. 4.

Comparing and contrasting the three surfactant replacement drugs currently in use in the United States with relation to: 5. Brand naming 6. Indications 7. Contraindications 8. Side effects/adverse reaction 9. Dosage and route of administration 10. Suggesting the appropriate surface-active agent, including dosage and method of delivery, given a patient case study. 11. Listing the most common indications for the use of aerosolized antimicrobial agents. 12. Describing the disadvantages or limitations of aerosol administration of antimicrobial drugs. 13. Naming the FDAapproved aerosolized antimicrobial agents and special equipment required for administration of each. 14. Describing contraindications and side effects of each drug that may be administered by aerosol as an antimicrobial agent. 15. Suggesting the most appropriate antimicrobial therapy, including the drug of choice, route of delivery, and recommending dosage, given a patient case study. 16. Describing the purpose of lidocaine use during a bronchoscopy. 17. Composing a plan for the use of lidocaine during bronchoscopy including strength, route of administration, and maximum dose. 18. Listing drugs used in performing "bronchial challenge" pulmonary function studies, including generic naming, actions, contraindications, and side effects/hazards. 19. Describing the role and differences between methacholine and mannitol when used for bronchial challenge testing. 20. Creating a plan for using inhaled nitric oxide and inhaled epoprostenol as selective vasodilators, dosage, and method of administration and monitoring for adverse effects. 21. Describing smoking cessation strategies and given a patient case be able to recommend appropriate pharmacologic smoking cessation therapy and instructions for use.

Competency 3: The student will describe the foundations of critical care pharmacotherapy related to advanced cardiac life support, cardiovascular, renal, endocrine, and central nervous system as well as antimicrobial pharmacology by:

- 1. Communication
- 2. Numbers / Data
- 3. Critical thinking
- 4. Information Literacy
- 5. Ethical Issues
- 6. Computer / Technology Usage
- 1. 1. Identifying the steps of rapid sequence intubation and summarizing what actions and/or medications are administered at each step. 2. Explaining the mechanism of action of neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. 3. Listing the medications used for pain management in the intensive care unit and identifying possible adverse effects associated with these agents. 4. Assessing the indications for deep sedation and light sedation and listing appropriate medications for each indication. 5. Explaining the rationale between coordinating daily sedation vacations with spontaneous breathing trials. 6. Distinguishing between the various types of shock and identifying the need for vasopressor therapy. 7. Explaining the differences in action and adverse effects between available vasoactive agents used for shock. 8. Indicating which advanced cardiovascular life support (ACLS) medications can be administered via an endotracheal tube and describing the proper administration technique. 9. Comparing the management of pulseless ventricular fibrillation/ventricular tachycardia with pulseless electrical activity/asystole cardiac arrest. 10. Suggesting the most appropriate ACLS therapy, including the drug of choice and route of administration, given a patient case study. 11. Describing the basic physiology of the nephron and how it is related to the pathophysiology of hypertension. 12. Describing the mechanism of action of each class of

- diuretics and be able to determining the most appropriate class to use for the treatment of pulmonary edema. 13. Defining heart failure with reduced ejection fraction and coronary artery disease. 14. Identifying the drug classes used in the treatment of heart failure with reduced ejection fraction. 15. Defining arrhythmia and listing the different types and most common causes of arrhythmias. 16. Describing the classification of antiarrhythmic drugs. 17. Describing the classification of antianginal drugs. 18. Describing the process of coagulation and how it is affected by anticoagulants. 19. Describing the classification of anticoagulant drugs.
- 2. 1. Describing the general anatomy of the central nervous system and listing the functions of each area. 2. Comparing the uses, mechanisms of action, and adverse effects of barbiturates and benzodiazepines. 3. Identifying factors that can enhance the effects of barbiturates and benzodiazepines. 4. Recommending a drug therapy for the treatment of respiratory depression caused by an acute opioid overdose. 5. Defining the term general anesthesia and listing the properties of an ideal general anesthetic. 6. Defining the term conscious sedation and describing the patient monitoring requirements.
- 3. 1. Summarizing the overall effects, therapeutic uses, and side effects of the glucocorticoids. 2. Describing the overall function of the pancreas and explaining the functions of insulin and glucagon. 3. Describing the role of the pancreatic enzymes in cystic fibrosis. 4. Comparing the pathogenesis of the two types of diabetes mellitus (DM). 5. Describing the relationship between antigen-antibody reactions, mast cells, and histamine. 6. Identifying the overall effects of histamine and listing the locations and types of histamine receptors. 7. Distinguishing between the common uses and the adverse

- effects of first- and second-generation antihistamines.
- 4. 1. Defining the terms antibacterial, antimicrobial, antiviral, antifungal, bacteriostatic, and bactericidal. 2. Summarizing the principles of appropriate use of antibiotics with regard to empiric and definitive therapy. 3. Identifying the microorganisms that cause upper and lower respiratory tract infections and determining appropriate drug therapy to treat these infections. 4. Comparing and contrasting antibiotic spectrums and common adverse effects. 5. Identifying the three categories of antifungal drugs, along with examples of adverse effects. 6. Describing the overall approach to treatment of viral infections and listing examples of antiviral drugs, along with therapeutic uses and adverse effects. 7. Recommending an appropriate treatment regimen for the management of tuberculosis and common side effects of each drug.

Updated: FALL TERM 2022